https://www.selleckchem.com/erk.html
Long-term safety data are of particular interest for any newly approved treatment in multiple sclerosis such as cladribine tablets 10mg (MAVENCLAD®; 3.5mg/kg cumulative dose over 2 years, referred to as cladribine tablets 3.5mg/kg), which is approved in Europe and the USA. Here we provide the final report on the integrated analysis of the safety profile of cladribine tablets 3.5mg/kg from the clinical development program, including final data from the PREMIERE registry. Safety data for cladribine tablets 3.5mg/kg from three previously reported Phase
Curtir
Comentario
Compartilhar
